Mesoblast

Mesoblast Accounts Payable

The Accounts Payable of Mesoblast (MSB.AX) as of Nov 19, 2026 is 34.51 M USD. In the previous year, Accounts Payable was 19.08 M USD — a change of 80.84% (higher).

Accounts Payable

34.51 MUSD

YoY

80.84%

Last updated:

Accounts Payable of Mesoblast is 2026 34.51 M USD. Accounts Payable of Mesoblast was 2025 19.08 M USD. It decreases by 80.84% higher compared to the previous year.

The Mesoblast Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
13.06 M USD
Jan 1, 2020
24.97 M USD
Jan 1, 2021
19.60 M USD
Jan 1, 2022
23.08 M USD
Jan 1, 2023
20.15 M USD
Jan 1, 2024
7.07 M USD
Jan 1, 2025
19.08 M USD
Jan 1, 2026
34.51 M USD
The Mesoblast Accounts Payable history
YEARAccounts PayableYoY
34.51 MUSD+80.84%
19.08 MUSD+169.90%
7.07 MUSD-64.90%
20.15 MUSD-12.71%
23.08 MUSD+17.76%
19.60 MUSD-21.52%
24.97 MUSD+91.21%
13.06 MUSD-30.98%
18.92 MUSD-13.23%
21.81 MUSD-19.70%
27.16 MUSD-3.85%
28.24 MUSD+36.28%
20.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

Accounts Payable of Mesoblast is 34.51 M USD in 2026.

Accounts Payable of Mesoblast changed from 19.08 M USD to 34.51 M USD, representing a 80.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Mesoblast since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mesoblast

All Key Metrics — Mesoblast